| |
| |
|
| Insider
Information: |
Korenberg Matthew E |
| Relationship: |
President & Chief Oper... |
| City: |
La Jolla |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
86,263 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$7,398,778 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
86,263 |
|
|
| Total
Value |
$7,398,778 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Ligand Pharmaceuticals Inc |
LGND |
President & Chief Oper... |
2024-05-14 |
86,263 |
2015-08-06 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
49 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 2
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| LGND |
Ligand Pharmaceuticals In... |
VP, Finance and CFO |
• – – |
2015-08-06 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
6,000 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
VP, Finance and CFO |
• – – |
2016-02-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,870 |
9,870 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
VP, Finance and CFO |
• – – |
2016-06-30 |
4 |
A |
$87.10 |
$17,072 |
D/D |
196 |
10,066 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
VP, Finance and CFO |
• – – |
2016-12-30 |
4 |
A |
$86.37 |
$3,455 |
D/D |
40 |
10,106 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
VP, Finance and CFO |
• – – |
2017-06-30 |
4 |
A |
$87.13 |
$21,171 |
D/D |
243 |
15,315 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
VP, Finance and CFO |
• – – |
2017-08-06 |
4 |
D |
$122.06 |
$74,335 |
D/D |
(609) |
14,706 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
VP, Finance and CFO |
• – – |
2017-11-17 |
4 |
S |
$142.63 |
$935,510 |
D/D |
(6,559) |
8,147 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
VP, Finance and CFO |
• – – |
2017-12-28 |
4 |
A |
$0.00 |
$0 |
D/D |
3,750 |
11,897 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
VP, Finance and CFO |
• – – |
2017-12-28 |
4 |
D |
$138.66 |
$212,150 |
D/D |
(1,530) |
10,367 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
EVP,Finance & Strategy and CFO |
• – – |
2018-02-15 |
4 |
D |
$157.18 |
$106,882 |
D/D |
(680) |
9,687 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
EVP,Finance & Strategy and CFO |
• – – |
2018-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
3,074 |
12,761 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
EVP,Finance & Strategy and CFO |
• – – |
2018-03-06 |
4 |
D |
$165.87 |
$91,229 |
D/D |
(550) |
14,215 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
EVP,Finance & Strategy and CFO |
• – – |
2018-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
2,004 |
14,765 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
EVP,Finance & Strategy and CFO |
• – – |
2018-06-29 |
4 |
A |
$117.84 |
$21,210 |
D/D |
180 |
14,395 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
EVP,Finance & Strategy and CFO |
• – – |
2018-08-06 |
4 |
D |
$226.74 |
$189,555 |
D/D |
(836) |
13,559 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
EVP,Finance & Strategy and CFO |
• – – |
2018-08-29 |
4 |
OE |
$85.79 |
$990,017 |
D/D |
11,540 |
25,099 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
EVP,Finance & Strategy and CFO |
• – – |
2018-08-29 |
4 |
S |
$256.69 |
$4,712,060 |
D/D |
(18,357) |
6,742 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
EVP,Finance & Strategy and CFO |
• – – |
2019-01-23 |
4 |
D |
$111.78 |
$148,109 |
D/D |
(1,325) |
10,065 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
EVP,Finance & Strategy and CFO |
• – – |
2019-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
4,648 |
10,677 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
EVP,Finance & Strategy and CFO |
• – – |
2019-02-11 |
4 |
A |
$0.00 |
$0 |
D/D |
6,404 |
16,469 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
EVP,Finance & Strategy and CFO |
• – – |
2019-02-15 |
4 |
D |
$120.86 |
$140,923 |
D/D |
(1,166) |
15,303 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
EVP,Finance & Strategy and CFO |
• – – |
2019-06-28 |
4 |
A |
$97.03 |
$17,659 |
D/D |
182 |
16,651 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
EVP,Finance & Strategy and CFO |
• – – |
2019-09-03 |
4 |
B |
$86.18 |
$43,091 |
D/D |
500 |
17,151 |
2.74 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
EVP,Finance & Strategy and CFO |
• – – |
2019-12-20 |
4 |
A |
$0.00 |
$0 |
D/D |
4,979 |
20,995 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
EVP,Finance & Strategy and CFO |
• – – |
2019-12-20 |
4 |
D |
$105.87 |
$223,809 |
D/D |
(2,114) |
20,016 |
0 |
- |
|
49 Records found
|
|
Page 1 of 2 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
